Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Having examined the options trading patterns of Novo Nordisk, our attention now turns directly to the company. This shift ...

A new survey has shown which companies in Denmark are trusted the most and least. Novo Nordisk is at the top, followed by ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Approval Drop. In this article, we ...

The manufacturer of the weight loss jab Wegovy has been reprimanded for allegedly failing to disclose or accurately report ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

Novo Nordisk is growing its India-based global business services to fill out vertical stacks, expand horizontal functions, ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) released its fourth-quarter and full-year earnings report on Feb. 5. The Denmark-based company performed pretty well, leading to a post-earnings jump ...

So, despite mounting competition, the Denmark-based drugmaker should remain a leader in GLP-1 drugs. Novo Nordisk has been looking to diversify its lineup in recent years, and is developing ...